Fig. 1 · Structure

Documents & Downloads

Estradiol dipropionate (17-Beta-Estradiol-3,17-Dipropionate)

Cat. No. A17791 CAS 113-38-2
Estradiol dipropionate is a semisynthetic, steroidal estrogen.

In Stock

Publications for Estradiol dipropionate

2 publications citing this product

  1. Jingyeong Shin, .et al. , Chemical Engineering Journal, 2023, December
  2. Yuanqin Zhang, .et al. , Cancers (Basel), 2023, Dec 2;15(23):5691 PMID: 38067394

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Estradiol dipropionate (17-Beta-Estradiol-3,17-Dipropionate) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Estradiol dipropionate (17-Beta-Estradiol-3,17-Dipropionate) from 2 published references. In vitro models include differentiated rat L6 skeletal muscle cells.

Estradiol dipropionate (17-Beta-Estradiol-3,17-Dipropionate) In Vitro Studies

Estradiol dipropionate increased glucose uptake in differentiated rat L6 cells, including an insulin-resistant model, during a 30 min exposure. Acute MTT measurements showed no significant viability reduction at 10–100 μM. These cell assays do not demonstrate glucose lowering in animals or patients. [1]

In L6 cells, 10–100 μM estradiol dipropionate increased PKC and AMPK phosphorylation after 30 min, while Akt phosphorylation did not increase significantly. These results describe signaling associations; estrogen-receptor dependence and a causal pathway assignment were not established by the adopted experiments. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Glucose uptake in normal and insulin-resistant L6 cells

Cell-based study · Differentiated rat L6 skeletal muscle cells; normal and insulin-resistant conditions [1]

EDP increased the glucose-uptake assay readout in normal and insulin-resistant L6 cells. Insulin responsiveness was reduced in the insulin-resistant model. Acute MTT measurements showed no significant viability change at the tested concentrations; this does not establish long-term safety.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative glucose uptake and acute MTT viability in normal L6 cellsDirection versus control Glucose uptake increased at 10, 30, 50 and 100 μM EDP; MTT viability: NS (p > 0.05) at these concentrations.[1]
Glucose uptake under insulin-resistant conditionsDirection versus insulin-resistant control 10 μM EDP increased uptake; 100 nM insulin alone was not significantly different from the insulin-resistant control.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Normal-cell assays: 10, 30, 50 and 100 μM EDP; insulin-resistant assay: 10 μM EDP. Insulin positive comparator: 100 nM.
Exposure duration
30 min EDP exposure after 2 h serum removal.
Method
Separate EDP, insulin and insulin + EDP groups, with untreated/blank controls.
Co-treatment
Figure 1C includes insulin + EDP; single-agent EDP findings are retained separately.
Reported limits
EDP solvent and solvent-matched control are not specified in Methods 4.1–4.3. Figure 1 does not state a panel-specific biological n; Methods describe 10 wells per group and experiments repeated more than three times, which are not treated as 10 independent biological replicates.
Methods and source locations

Compound reported in the paper: Estradiol dipropionate; Compound label in the paper: EDP

Published cellular results for the stated EDP material; no validation of Adooq product lots or clinical efficacy.

Results 2.1; Figure 1A–D; Methods 4.1–4.3 and 4.7

Relative glucose uptake and acute MTT viability in normal L6 cells: Residual medium glucose measured by glucose oxidase/peroxidase colorimetry at 505 nm; MTT readout at 492 nm. No exact bar heights extracted. — Figure 1B and 1D; Results 2.1

Glucose uptake under insulin-resistant conditions: Insulin-resistant model generated by 1 μM insulin for 1 day; blank, insulin, EDP and insulin + EDP groups shown. No combination synergy claim. — Figure 1C; Results 2.1; Methods 4.3

Signaling phosphorylation after EDP exposure

Cell-based study · Differentiated rat L6 skeletal muscle cells [1]

EDP exposure was associated with increased pan-PKC and AMPK phosphorylation. Akt phosphorylation did not increase significantly, despite a clear insulin positive-control response. These are cellular phosphorylation endpoints, not direct enzyme activation or binding assays; they do not establish estrogen-receptor dependence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Pan-PKC and AMPK phosphorylationImmunoblot direction versus control Increased at 10, 30 and 100 μM EDP after 30 min.[1]
Akt phosphorylationp-Akt/Akt NS versus control at 10, 30 and 100 μM EDP; 100 nM insulin increased p-Akt/Akt.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10, 30 and 100 μM EDP.
Exposure duration
30 min; Methods 4.5 specifies 2 h serum removal.
Method
Cell treatment followed by immunoblot analysis.
Reported limits
EDP solvent is not specified. Panel-specific biological n is not stated in Figure 4; Methods 4.7 reports experiments repeated more than three times and mean ± standard error. Inhibitor panel 4D is excluded because its caption swaps inhibitor assignments relative to Results 2.4.
Methods and source locations

Compound reported in the paper: Estradiol dipropionate; Compound label in the paper: EDP

Published cellular results for the stated EDP material; no validation of Adooq product lots or clinical efficacy.

Results 2.4; Figure 4A–C; Methods 4.1, 4.2, 4.5 and 4.7

Pan-PKC and AMPK phosphorylation: p-PKC normalized to β-actin; p-AMPK normalized to total AMPK. Positive controls: PMA 200 μM (panel A label) and metformin 100 μM. — Figure 4A,C; Results 2.4

Akt phosphorylation: Immunoblot with total Akt and β-actin controls; no exact densitometry values inferred. — Figure 4B; Results 2.4

Estradiol dipropionate (17-Beta-Estradiol-3,17-Dipropionate) In Vivo Studies

In ovariectomized Parkes mice, an estradiol dipropionate formulation given subcutaneously at 20 μg per female daily increased uterine glycogen and decreased vaginal glycogen relative to untreated controls. The four 7/14-day treatment-timing subgroups did not differ significantly. The study lacked an explicitly described vehicle-injection control and did not assess systemic glucose lowering. [2]

Opposite uterine and vaginal glycogen responses in ovariectomized mice

Animal study · Virgin female Parkes (P) mice, 70–100 days old, bilaterally ovariectomized; three mice per subgroup [2]

The EDP formulation was associated with higher uterine and lower vaginal glycogen relative to untreated ovariectomized controls. No significant differences were reported among the four EDP timing subgroups, or between the two control subgroups. The study does not establish glucose lowering or exclusive attribution to the ester independently of formulation and vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Uterine glycogenμg/mg wet tissue weight; mean ± SEM A1: 0.869 ± 0.061; A2: 0.878 ± 0.051; B1: 2.437 ± 0.063 (P < 0.001 vs A1); B2: 2.263 ± 0.170 (P < 0.005 vs A1); B3: 2.229 ± 0.026 (P < 0.001 vs A2); B4: 2.326 ± 0.052 (P < 0.001 vs A2).[2]
Vaginal glycogenμg/mg wet tissue weight; mean ± SEM A1: 2.480 ± 0.072; A2: 2.368 ± 0.115; B1: 0.584 ± 0.008; B2: 0.706 ± 0.045; B3: 0.664 ± 0.040; B4: 0.547 ± 0.093. Each B subgroup P < 0.001 versus its designated A control.[2]
Comparison of treatment and ovariectomy timing subgroupsReported significance A1 versus A2: not significant; intra-group B1–B4 comparisons: not significant in both tissues.[2]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Daily
Vehicle
Ovocyclin diluted in olive oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
B1 EDP
20 μg per female per day
A1 (7-day ovariectomized control)Uterine glycogen 2.437 ± 0.063; vaginal glycogen 0.584 ± 0.008 μg/mg wet weight (mean ± SEM).[2]
B2 EDP
20 μg per female per day
A1 (7-day ovariectomized control)Uterine glycogen 2.263 ± 0.170; vaginal glycogen 0.706 ± 0.045 μg/mg wet weight (mean ± SEM).[2]
B3 EDP
20 μg per female per day
A2 (14-day ovariectomized control)Uterine glycogen 2.229 ± 0.026; vaginal glycogen 0.664 ± 0.040 μg/mg wet weight (mean ± SEM).[2]
B4 EDP
20 μg per female per day
A2 (14-day ovariectomized control)Uterine glycogen 2.326 ± 0.052; vaginal glycogen 0.547 ± 0.093 μg/mg wet weight (mean ± SEM).[2]
B1 EDP
Model: Parkes female mice; treatment started 7 days after ovariectomy; three mice per subgroup.
Treatment course: 7 days
Reported limits: No explicit vehicle injection control; no randomization or blinding stated.
B2 EDP
Model: Parkes female mice; treatment started 7 days after ovariectomy; three mice per subgroup.
Treatment course: 14 days
Reported limits: No explicit vehicle injection control; no randomization or blinding stated.
B3 EDP
Model: Parkes female mice; treatment started 14 days after ovariectomy; three mice per subgroup.
Treatment course: 7 days
Reported limits: No explicit vehicle injection control; no randomization or blinding stated.
B4 EDP
Model: Parkes female mice; treatment started 14 days after ovariectomy; three mice per subgroup.
Treatment course: 14 days
Reported limits: No explicit vehicle injection control; no randomization or blinding stated.
Methods and source locations

Compound reported in the paper: Estradiol dipropionate; Compound label in the paper: estradiol dipropionate / Ovocyclin

Tissue glycogen responses in the specified ovariectomized mouse formulation model; no systemic hypoglycemic or clinical inference.

Materials and Methods pp.318–320; Tables I–II pp.318–319; Results pp.320–321; Figures 2–3 p.320

Uterine glycogen: Montgomery glycogen method; Student’s t test. Table says mean of three individual determinations; Methods says three mice per subgroup. — Table II p.319; Tables I and Figure 2 caption for subgroup definitions; Results pp.320–321

Vaginal glycogen: Montgomery method; comparisons B1/B2 versus A1 and B3/B4 versus A2, as specified in the Table II footnote. — Table II p.319; Figure 3 caption p.320; Results p.321

Comparison of treatment and ovariectomy timing subgroups: No inference of equivalence or absence of an earlier time-dependent response; only the studied 7/14-day conditions were assessed. — Table II footnote p.319; Results pp.320–321

B1 EDP · Tables I–II pp.318–319; Materials and Methods pp.318–320

B2 EDP · Tables I–II pp.318–319; Materials and Methods pp.318–320

B3 EDP · Tables I–II pp.318–319; Materials and Methods pp.318–320

B4 EDP · Tables I–II pp.318–319; Materials and Methods pp.318–320

Specifications

Manufacturer Adooq Bioscience
CAS Number 113-38-2
Formula C24H32O4
Molecular Weight 384.52
Synonyms Estroici; Estronex; Follicyclin P; 17-Beta-Estradiol-3,17-Dipropionate
SMILES
C[C@@]12[C@@H](OC(CC)=O)CC[C@@]1([H])[C@]3([H])CCC4=C(C=CC(OC(CC)=O)=C4)[C@@]3([H])CC2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 18 mg/mL (46.81 mM)
Water Insoluble
Ethanol 17 mg/mL (44.21 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Estradiol dipropionate (17-Beta-Estradiol-3,17-Dipropionate) Research References

  1. [1] Yanhong Yao, Xinzhou Yang, Jinhua Shen, et al. Glucose Uptake Is Increased by Estradiol Dipropionate in L6 Skeletal Muscle Cells Pharmaceuticals (Basel) (2023). PMID: 36678522 DOI: 10.3390/ph16010025 Source material
  2. [2] G. Tripathi. Effect of estradiol dipropionate on uterine and vaginal glycogen content of Parkes (P) mice Indian Journal of Physiology and Pharmacology (1983). PMID: 6678239 Source material

Publications

2 publications citing this product

  1. Jingyeong Shin, .et al. , Chemical Engineering Journal, 2023, December
  2. Yuanqin Zhang, .et al. , Cancers (Basel), 2023, Dec 2;15(23):5691 PMID: 38067394

Added to your cart

View Cart Checkout
Loading...